Valganciclovir
Cytomegalovirus Infection
The Methodist Hospital Research InstituteSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Cytomegalovirus Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Foscarnet City of Hope Medical Center | Phase 4 | BB |
Ganciclovir City of Hope Medical Center | Phase 3 | BB |
Cmvpp65-A*0201 Peptide Vaccine City of Hope Medical Center | Phase 2 | B |
Letermovir Fernanda P Silveira, MD, MS | Phase 2 | B |
Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 13 →
Same molecule, other indications
Valganciclovir is also rated in:
Epstein-Barr virus-associated lymphoproliferative disorderDormant
B
Indicative · Phase 2
61 / 100
View asset →chronic lymphocytic leukemia/small lymphocytic lymphomaActive
B
Indicative · Phase 4
58 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →